about
Improved corneal wound healing through modulation of gap junction communication using connexin43-specific antisense oligodeoxynucleotides.Role of gap junctions in chronic pain.Injectable implants for the sustained release of protein and peptide drugs.Dendrimers for gene delivery--a potential approach for ocular therapy?Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems.Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.Ocular delivery systems for topical application of anti-infective agents.Connexin43 in retinal injury and disease.In vitro and ex vivo corneal penetration and absorption models.Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.Light-responsive in situ forming injectable implants for effective drug delivery to the posterior segment of the eye.Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride.Modern approaches to the ocular delivery of cyclosporine A.Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.Cytotoxicity considerations and electrically tunable release of dexamethasone from polypyrrole for the treatment of back-of-the-eye conditions.Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.Cytotoxicity and vitreous stability of chemically modified connexin43 mimetic peptides for the treatment of optic neuropathy.Ex vivo and In vivo Evaluation of Chitosan Coated Nanostructured Lipid Carriers for Ocular Delivery of Acyclovir.Electro-responsive macroporous polypyrrole scaffolds for triggered dexamethasone delivery.Phase transition of a microemulsion upon addition of cyclodextrin - applications in drug delivery.Characterization and evaluation of β-glucan formulations as injectable implants for protein and peptide delivery.Immunohistochemical Characterization of Connexin43 Expression in a Mouse Model of Diabetic Retinopathy and in Human Donor Retinas.Drug-device combination approaches for delivery to the eye.Medicated ocular bandages and corneal health: potential excipients and active pharmaceutical ingredients.Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina.Sustained intravitreal delivery of connexin43 mimetic peptide by poly(D,L-lactide-co-glycolide) acid micro- and nanoparticles--Closing the gap in retinal ischaemia.Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia.Synergistic effect of chemical penetration enhancer and iontophoresis on transappendageal transport of oligodeoxynucleotides.Ion-activated in situ gelling systems for antisense oligodeoxynucleotide delivery to the ocular surface.In vitro release characteristics and cellular uptake of poly(D,L-lactic-co-glycolic acid) nanoparticles for topical delivery of antisense oligodeoxynucleotides.Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study.Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release.Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS.Effects of enzymatic degradation on dynamic mechanical properties of the vitreous and intravitreal nanoparticle mobility.Micelle directed chemical polymerization of polypyrrole particles for the electrically triggered release of dexamethasone base and dexamethasone phosphate.PLGA nanoparticles for intravitreal peptide delivery: statistical optimization, characterization and toxicity evaluation.Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: Modelling signs of diabetic retinopathyDevelopment of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug deliveryImaging Techniques and their Role in Dosage form Design and Drug Delivery ResearchOcular drug delivery-eye on innovation
P50
Q34128306-96BDDF54-0D3E-4F99-AD80-7E19F3A2E836Q37942479-A35BD073-EE26-4605-833C-55E93AF08F11Q38081610-E55F35BE-DEA4-4798-8859-F5D0F269A9B0Q38196447-6853B95D-64A2-46D6-A1AC-163A03F043A2Q38259425-C070D6BC-5000-4D46-AAE8-06A276CA7137Q38353326-071AC793-2C76-4032-98D4-AF05CA181AEDQ38577846-8B0E5B16-C768-4C07-A6B3-6367D2749E05Q38598207-44E09343-0502-4A09-894D-AAF01BE7D941Q38695101-1612FE91-48CB-4197-A2A5-D11FF8929943Q38750282-908E7754-6DFD-45C7-8A9A-4C03E4CA6F15Q38769853-A60EA7C1-D2FA-4772-B092-3F9C44598580Q38797850-E4E61528-9A81-40D0-BFF4-A38B1C5871FBQ38808718-0AF76D71-BC27-4434-A609-3938B81ADAC9Q38829320-D607E358-CB64-4C66-AD2A-D76F635CBE62Q38906809-775BA08F-A0C7-45A0-9FDE-18C774C7F3D5Q39087808-790D7714-DAAF-47E2-863A-A201C30B9CF9Q39148880-DAAF3F16-D4CB-44F5-8221-DAB2F172105DQ40909699-BEE516F0-ABC1-4A36-9D4D-AF7C7019D8D6Q41124274-E2A79735-F981-4CE1-92A0-D900BDEDB8FCQ41596731-DC34EA15-8ABC-499E-9305-28F248AD5311Q43954070-B5BCFF73-8B21-43CE-B2FB-3711CEF4AAC5Q47176174-E73B6A37-77AF-4EA4-BCB7-708F1618FD9BQ47750652-3A2BE41E-9E45-4BB8-B75F-294417816B0AQ48122498-D5FACFAA-9D22-40D0-96AC-EFB55C2C5F14Q48134125-2C7FB945-B75E-48C9-BA3A-52B82138E457Q48416361-5EFB1BB4-09E2-482F-9D3C-59E95F5C7265Q50250404-B5FF8F2F-6AE4-43AC-B112-9F1074D44BCFQ50488688-154E62C2-1000-4C1D-B8F6-3C11A3557F57Q50510359-0381F9B4-2EF7-4760-B98D-EFA8C84B2C35Q50518218-9E1DCDDA-1D0F-461B-9C81-15DE4AE76FC4Q50523915-D402090B-6718-4A00-BF09-6B61B69ED7EAQ50523919-4C3AB399-0FD2-4320-9276-5ADF5AF55636Q51667962-9B441E26-C728-40DD-A71A-979FEFE125B6Q51759876-7AA2ABF7-9E2A-40F9-9F83-5EB7D9D5C0AEQ52629733-8FBDAA47-A122-45D3-A1BE-2A7FF94D7D01Q54195898-D74BCE5D-C4ED-4369-B64D-E4B23BE32710Q58723006-4CD21587-73E5-47DD-9D86-AF3E0A396C81Q61979898-0C542498-EEA4-4A46-9151-88EB927DC06EQ62225634-01A4491C-1791-414B-8450-A182F9A9964AQ88600298-9000770C-E58A-48AF-93A1-D72CA5EF0CC5
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ilva D Rupenthal
@nl
Ilva D Rupenthal
@sl
Ilva D. Rupenthal
@en
Ilva D. Rupenthal
@es
type
label
Ilva D Rupenthal
@nl
Ilva D Rupenthal
@sl
Ilva D. Rupenthal
@en
Ilva D. Rupenthal
@es
prefLabel
Ilva D Rupenthal
@nl
Ilva D Rupenthal
@sl
Ilva D. Rupenthal
@en
Ilva D. Rupenthal
@es
P106
P1153
25227059400
P31
P496
0000-0001-5997-5994